

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Michael Jaff

Page 1/12

Tuesday, January 27, 2015

MAIN ARENA 1

- 08:00 – 09:30** **Symposium: Enhancing treatment in SFA & Pop lesions subsets with SUPERA**
supported with an educational grant from Abbott Vascular
CHAIRMAN:
Dierk Scheinert
MODERATOR:
Ramon Varcoe
Steven Kum
Chris Metzger
Peter Goverde
- 08:00 – 08:05 Introduction by the chairman
- 08:05 – 08:10 SUPERB – 3 year follow up
Lawrence Garcia
- 08:10 – 08:20 SUPERA data – long-term follow up/5 years
Dierk Scheinert
- 08:20 – 08:30 Evolving strategies and economic considerations in treatment of femoropopliteal arterial disease
Michael Jaff
- 08:30 – 08:40 A real world experience using SUPERA in long challenging lesions: patency results, deployment pitfalls and insights into mode of failure
Ramon Varcoe
- 08:40 – 08:45 Optimal implantation deployment for optimal clinical outcome
Chris Metzger
- 08:45 – 09:05 Live case transmission from Leipzig
- 09:05 – 09:30 The great debate: So many technologies – what is the optimal treatment for the SFA? (atherectomy, DCB, SNS, Covered, DES, SUPERA etc.)

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Michael Jaff

Page 2/12

Tuesday, January 27, 2015

TECHNICAL FORUM

09:00 – 12:30 **Deep Dive Session: Carotid revascularization**

CHAIRMAN:

Frank Veith
William Gray

MODERATOR:

Martin Storck
Bernhard Reimers
Klaus Mathias
Sumaira Macdonald
Dariusz Dudek

- 09:00 – 10:37 Focus on asymptomatic carotid stenoses
- 09:00 – 09:07 Revascularization in patients with asymptomatic carotid stenosis – What is best practice?
Marco Roffi
- 09:07 – 09:14 How good is current best medical therapy for stroke prevention in patients with asymptomatic carotid stenosis?
Dorothee Saur
- 09:14 – 09:21 Asymptomatic carotid stenosis: What will CREST 2 tell us what we don't already know?
Michael Jaff
- 09:21 – 09:28 A new life for carotid stenting? – The ACST-2 trial
Alison Halliday
- 09:28 – 09:35 A status update on SPACE II
Christian Reeps
- 09:35 – 09:42 How to pick the asymptomatic carotid stenosis at risk
Frans Moll
- 09:42 – 09:49 Management of carotid artery disease in patients undergoing cardiac procedures
Marco Roffi
- 09:49 – 09:56 Influence of coronary heart disease on patient outcome after CAS
Stanislav Bartus
- 09:56 – 10:03 Discussion

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Michael Jaff

Page 3/12

Tuesday, January 27, 2015

- | | |
|---------------|--|
| 10:03 – 10:37 | Live case transmission from Berlin |
| 10:37 – 12:30 | How to optimize outcome of carotid revascularization? |
| 10:37 – 10:44 | Filter protected carotid angioplasty: Prospective analysis of microscopic findings of embolic material and correlation with clinical and morphological characteristics in 400 cases Peter Huppert |
| 10:44 – 10:51 | Double filtration during carotid artery stenting: Reducing the risk of stroke William Gray |
| 10:51 – 10:58 | Carotid stenting with proximal protection in consecutive CAS patients Horst Sievert |
| 10:58 – 11:06 | The CARENET all-comer trial using the CGuard™ micronet-covered carotid embolic prevention stent Piotr Musialek |
| 11:06 – 11:39 | Live case transmission from Cotignola |
| 11:39 – 11:46 | The role of stent design for CAS: Does it affect post procedural neurologic events Eugenio Stabile |
| 11:46 – 11:53 | Evaluation and comparison of carotid and coronary artery plaque using IVUS virtual histology Andrej Erglis |
| 11:53 – 12:00 | Long-term follow-up of CAS: 5 year data of a single center all-comers registry Paolo Rubino |
| 12:00 – 12:07 | Best practice in CEA: Is there a way to make surgery even better? Gioachino Coppi |
| 12:07 – 12:14 | Carotid revascularization in Germany: Data from the national quality assurance programme on 30.000+ patients Martin Storck |
| 12:14 – 12:21 | Revascularization in recently symptomatic patients: How to achieve optimal results? Carlo Setacci |
| 12:21 – 12:28 | Despite current level 1 evidence – the outlook for an upsurge in CAS is bright Frank Veith |
| 12:28 – 12:30 | Discussion |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Michael Jaff

Page 4/12

Tuesday, January 27, 2015

MAIN ARENA 1

09:30 – 11:00

Changing paradigms and future concepts in peripheral interventions

CHAIRMAN:

Dierk Scheinert

Gary Ansel

MODERATOR:

Karl-Ludwig Schulte

Steven Kum

Erich Minar

Andrew Holden

Michael Jaff

Iris Baumgartner

09:30 – 10:00

Drug-coated balloons: Finally proven as the first-line therapy for femoro-popliteal de-novo lesions?

09:30 – 09:35

In.Pact-SFA clinical trial: Update on 1-year data

Gunnar Tepe

09:35 – 09:40

LEVANT II clinical trial: 2-year data

Dierk Scheinert

09:40 – 09:45

My take-home messages from LEVANT II and In.Pact SFA – a critical review

Michael Jaff

09:45 – 09:50

Panel discussion and vote

09:50 – 10:00

Live case transmission from Leipzig part I

10:00 – 11:00

Future prospects for DCB and alternative endovascular concepts

10:00 – 10:05

DCB + atherectomy: The ISAR STATH trial results

Massimiliano Fusaro

10:05 – 10:10

DCB + atherectomy for complex lesions: DEFINITIVE AR – Final data

Gunnar Tepe

10:10 – 10:15

Early look at the VISION Trial: OCT guided atherectomy using Avinger's Pantheris catheter

Arne Schwindt

10:15 – 10:20

The role of vessel preparation – insights from the Heidelberg PANTHER registry

Erwin Blessing

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Michael Jaff

Page 5/12

Tuesday, January 27, 2015

- | | |
|---------------|---|
| 10:20 – 10:25 | A future concept for drug delivery: The Mercator Bullfrog technology Dierk Scheinert |
| 10:25 – 10:43 | Live case transmission from Leipzig part II |
| 10:43 – 10:48 | Should all stents promote swirling flow? Thomas Zeller |
| 10:48 – 10:53 | The TOBA-trial 12 months results with the Tack-device for dissection sealing in the SFA Marc Bosiers |
| 10:53 – 11:00 | Biodegradable vascular scaffolds – how far have we come? Iris Baumgartner |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Michael Jaff

Page 6/12

Wednesday, January 28, 2015

MAIN ARENA 1

09:30 – 11:00 **Critical limb ischemia treatment 2014: Lessons learned, current status and future perspectives**

CHAIRMAN:

Dierk Scheinert
Peter Schneider

MODERATOR:

Iris Baumgartner
Renu Virmani
Andrew Holden
Yoshiaki Yokoi

Michael Jaff

- | | |
|---------------|---|
| 09:30 – 09:35 | The rationale for the “Endovascular First” concept and how to implement it Peter Schneider |
| 09:35 – 09:40 | Real world CLI practice: Update from the CRITISCH registry Theodosios Bisdas |
| 09:40 – 10:10 | The Angiosome concept: Pro and cons |
| 09:40 – 09:45 | The BEST-CLI Trial: Open vs. endovascular therapy for critical limb ischemia Michael Jaff |
| 09:45 – 09:50 | Revascularization of the wound-related artery is key Osamu Iida |
| 09:50 – 10:00 | Live case transmission from Leipzig part I |
| 10:00 – 10:05 | There is no proof for the angiosome concept Peter Huppert |
| 10:05 – 10:10 | Panel discussion and vote |
| 10:10 – 11:00 | Drug-coated balloons for BTK disease in critical limb ischemia – a failed concept? |
| 10:10 – 10:15 | One year after In.Pact Deep: Lessons learned from a failed trial Thomas Zeller |
| 10:15 – 10:20 | Safety of Paclitaxel balloon coatings: Insights from a pathologist Renu Virmani |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C



Michael Jaff

Page 7/12

Wednesday, January 28, 2015

- | | |
|---------------|--|
| 10:20 – 10:25 | Ongoing trials and future concepts for local drug delivery in BTK arteries Dierk Scheinert |
| 10:25 – 10:30 | Panel discussion and vote |
| 10:30 – 10:45 | Live case transmission from Leipzig part II |
| 10:45 – 10:50 | Destiny II: 12 months results with long segment DES treatment in BTK arteries Marc Bosiers |
| 10:50 – 10:55 | PES BTK 70: 12 months results with a paclitaxel-coated self-expandingstent in BTK arteries Marc Bosiers |
| 10:55 – 11:00 | Initial experience with absorbable drug-eluting vascular scaffolds in BTK arteries Ramon Varcoe |

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Michael Jaff

Page 8/12

Wednesday, January 28, 2015

MAIN ARENA 1

13:30 – 15:00 **Symposium: Lutonix® DCB – Discussion on pre-clinical safety studies, new insights from LEVANT2, Real World experience and the role of DCB in treatment of critical limb ischemia**
supported with an educational grant from CR BARD

CHAIRMAN:

Michael Jaff

MODERATOR:

Renu Virmani

Marcus Thieme

Marianne Brodmann

Jihad Mustapha

13:30 – 13:37 Not all DCBs are created equal: Side by side pre-clinical safety evaluation of leading DCBs
Renu Virmani

13:37 – 14:02 Live case transmission from Leipzig

14:02 – 14:09 New insights from LEVANT2: Randomized 12 month data and post hoc analysis
Dierk Scheinert

14:09 – 14:16 A first look and interim analysis of 12 month outcomes from the Real World Global SFA registry
Marcus Thieme

14:16 – 14:40 Live case transmission from Leipzig

14:40 – 14:47 Role of DCBs in treating critical limb ischemia and the enrollment update on-going Lutonix® BTK clinical trial
Marianne Brodmann

14:47 – 14:54 Discussion on physiology of CLI in utility of DCB in below-the-knee procedures
Jihad Mustapha

14:54 – 15:00 German single center experience with Lutonix® DCB in BTK
Sabine Steiner

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Michael Jaff

Page 9/12

Wednesday, January 28, 2015

MAIN ARENA 1

15:00 – 16:30 **VIVA @ LINC: Renal and visceral disease: pressing new dilemmas and pushing the field forward**

CHAIRMAN:

Chris Metzger

MODERATOR:

Michael Jaff

Tony Das

Peter Schneider

Felix Mahfoud

Michael Moche

Jos van den Berg

Henrik Schröder

15:00 – 15:05 Introduction by the chairman

15:05 – 15:13 CORAL trial aftermath: What do we do now? Renal revascularisation in perspective

Michael Jaff

15:13 – 15:33 Live case transmission from Teaneck

15:33 – 15:41 How to assess the hemodynamic importance of a renal artery stenosis

Felix Mahfoud

15:41 – 15:49 Endovascular treatment of mesenteric angina: Tips, tricks, and techniques

Chris Metzger

15:49 – 16:14 Live case transmission from Teaneck

16:14 – 16:22 Visceral artery aneurysms. The silent killer comes into focus now that we can find them and fix them

Michael Dake

16:22 – 16:30 Discussion and conclusion

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Michael Jaff

Page 10/12

Thursday, January 29, 2015

DISCUSSION FORUM

09:30 – 10:30 **Controversial issues and open questions in venous interventions**

CHAIRMAN:

Michael Dake

DISCUSSANT:

Sebastian Schellong

Nils Kucher

Michael Jaff

Gerard O'Sullivan

Cees Wittens

- 09:30 – 10:00 Venous interventions – Hype or reality?
- 09:30 – 09:38 Most patients are still best treated with anticoagulation – interventions are only justified in very selected cases!
Sebastian Schellong
- 09:38 – 09:46 The evidence for venous interventions is evolving – many patients do actually benefit!
Nils Kucher
- 09:46 – 09:54 How to select appropriate endpoints and measure success?
Michael Jaff
- 09:54 – 10:00 Discussion and conclusion
- 10:00 – 10:30 Are venous interventional techniques ready for prime-time?
- 10:00 – 10:08 Thrombus removal in acute and subacute thrombosis: How to achieve and the role of filter protection
Gerard O'Sullivan
- 10:08 – 10:16 Venous stenting: How does the optimal device look like and does it already exist?
Cees Wittens
- 10:16 – 10:24 What is the optimal time window for treating deep venous thrombosis – acute vs. subacute vs. chronic cases
Peter Schneider
- 10:24 – 10:30 Discussion and conclusion

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

Michael Jaff

Page 11/12

Thursday, January 29, 2015

DISCUSSION FORUM

- 12:30 – 13:30** **The great debate: Are all DCB equal?**
CHAIRMAN:
Michael Jaff
Dierk Scheinert
DISCUSSANT:
Gunnar Tepe
Renu Virmani
Stephan Duda
Marianne Brodmann
- 12:30 – 12:37 There are clear differences in DCB outcomes in the SFA for various coatings – DCB are not equal!
Gunnar Tepe
- 12:37 – 12:44 Lacking head-to-head trials comparing different DCB studies is comparing apples and oranges –
Results have been substantially affected by trial design
- 12:44 – 12:51 The relevance of Paclitaxel dose and coating for efficacy and safety
Renu Virmani
- 12:51 – 12:58 Whats next to come in the drug delivery space: Ongoing DCB programmes
Stephan Duda
- 12:58 – 13:05 Lessons learned from INPACT.Deep and why we should stay away from DCB for BTK interventions
Erich Minar
- 13:05 – 13:12 DCB are still a valid option to solve the challenge of BTK vessel patency: Lutonix BTK trials are
continuing
Marianne Brodmann
- 13:12 – 13:30 Discussion and conclusion

We are asking all faculty members to strictly respect the given time limits.

PROGRAMME

LEIPZIG
INTERVENTIONAL
COURSE

L I N C

The logo for LINC (Leipzig Interventional Network Course) features the letters 'L I N C' in a bold, sans-serif font. A large, dark blue, brush-stroke-like graphic element curves behind the letters, starting from the bottom left and sweeping upwards and to the right, passing behind the 'I' and 'N'.

Michael Jaff

Page 12/12

Thursday, January 29, 2015

DISCUSSION FORUM

15:00 – 16:30

VIVA @ LINC: The worst complication I had this year. What did I learn?

CHAIRMAN:

Michael Jaff

DISCUSSANT:

Michael Dake

John Kaufman

Chris Metzger

15:00 – 16:30

This is a case-based session focussing on what we like best ... real cases with challenges and complications that make the experts sweat. In this amphitheatre setting, audience participation is encouraged and step-by-step case management is featured and discussed. This round room setting is dedicated to controversial or interactive talk-show-like sessions.

We are asking all faculty members to strictly respect the given time limits.